ALLK:NSD-Allakos Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 113.14

Change

+1.76 (+1.58)%

Market Cap

USD 6.09B

Volume

0.29M

Average Target Price

USD 171.00 (+51.14%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.65 (-0.31%)

USD54.19B 20.26 15.08
MRNA Moderna, Inc

+1.08 (+0.82%)

USD52.46B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

+2.65 (+0.59%)

USD47.86B 14.64 11.87
ALXN Alexion Pharmaceuticals, Inc

+0.27 (+0.18%)

USD32.58B 54.48 33.22
BGNE BeiGene, Ltd

-15.33 (-5.03%)

USD29.17B N/A N/A
SGEN Seagen Inc

-2.48 (-1.68%)

USD26.80B 43.90 37.70
RPRX Royalty Pharma plc

-1.23 (-2.82%)

USD26.45B 22.60 14.17
BNTX BioNTech SE

-2.10 (-2.16%)

USD25.28B -99,999.99 N/A
GMAB Genmab A/S

-1.63 (-5.01%)

USD22.05B 26.59 3.17
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ALLK

Symbol Name Weight Mer Price(Change) Market Cap
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

-1.91 (-3.66%)

USD0.28B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.19% 14% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.19% 14% F 8% F
Trailing 12 Months  
Capital Gain 90.02% 76% C 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 90.02% 76% C 80% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 36.66% 71% C- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.66% 71% C- 84% B
Risk Return Profile  
Volatility (Standard Deviation) 43.94% 64% D 32% F
Risk Adjusted Return 83.42% 96% A 88% B+
Market Capitalization 6.09B 93% A 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 15.01 17% F 13% F
Price / Cash Flow Ratio -53.47 91% A- 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -28.83% 79% C+ 31% F
Return on Invested Capital -27.31% 77% C+ 27% F
Return on Assets -17.88% 69% D+ 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 10.29 11% F 5% F
Short Percent 13.54% 15% F 13% F
Beta 1.03 71% C- 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.